EQU-001

DRUG4 trials

Sponsors

Equilibre Biopharmaceuticals B.V.

Conditions

EpilepsyFocal Onset SeizuresSafety Issues

Phase 1

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

CompletedNCT05004571

Equilibre Biopharmaceuticals B.V.Safety Issues

Start: 2021-07-06End: 2021-09-04Updated: 2023-02-01

Phase 2

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

Equilibre Biopharmaceuticals B.V.Epilepsy

Start: 2021-08-31End: 2023-10-11Updated: 2023-05-15

Study of EQU-001 for Uncontrolled Focal Onset Seizures

TerminatedNCT05473442

Equilibre Biopharmaceuticals B.V.Focal Onset Seizures

Start: 2022-12-27End: 2023-07-01Updated: 2023-12-21

A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures

CompletedCTIS2022-500302-18-00

Equilibre Biopharmaceuticals B.V.Epilepsy

End: 2023-07-07Target: 123Updated: 2023-06-21